window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Digital Health

  • Clinical Development,Clinical studies,Digital Health,FDA,Medical devices,Technology and platforms

    Viz.ai, Johnson & Johnson strike US chronic subdural hematoma AI deal

    Viz.ai has entered a collaboration with Johnson & Johnson to [...]

    April 22, 2026
  • Clinical studies,Digital Health,Drug Delivery & Formulation,Neurosciences

    Study confirms Nerivio REN wearable safe with continuous glucose monitoring devices

    A new study confirms that Theranica’s Nerivio REN wearable for [...]

    February 25, 2026
  • Artificial Intelligence,Digital Health,Funding,Healthcare leadership,Pharmaceuticals and therapeutics

    Brainomix extends Series C to $25.4M to support US expansion

    Brainomix has extended its Series C financing by $6.5M (£4.8M), [...]

    February 24, 2026
  • Clinical Development,Data Management,Digital Health,Movers & Shakers,Technology and platforms

    IgniteData appoints Laura Hilty as CSO and Joe Lengfellner as CPO amid Series A funding close

    IgniteData has appointed Laura Hilty as chief strategy officer and [...]

    February 11, 2026
  • Biotech,Digital Health,Technology and platforms

    Research finds scientists view ELNs as ‘glorified filing cabinets’, driving duplication and shadow AI use

    A new survey by Sapio Sciences has found widespread frustration [...]

    January 30, 2026
  • Clinical Trials,Digital Health,Patient Centricity,Real world evidence,Technology and platforms

    Kayentis and Ametris partner on integrated eCOA and wearable adherence platform

    Kayentis and Ametris have announced a strategic partnership to integrate [...]

    January 30, 2026
  • Digital Health,Healthcare leadership,Medical devices,Mental health,Regulatory Affairs

    Mental health systems strain as demand and funding shifts drive push for multimodal care

    Mental health systems in the US and UK have entered [...]

    January 29, 2026
  • Clinical Development,Digital Health,Patient Centricity,Technology and platforms

    Beauregard Health System unifies post-appointment medication messaging with Artera and DrFirst integration

    Beauregard Health System has integrated Artera’s patient communication platform and [...]

    January 27, 2026
  • Central Nervous System,Digital Health,Medical devices,Patient Centricity,Pharmaceuticals and therapeutics

    NeuroVice seizure oral injury device now available through BlinkRx

    The PATI device from NeuroVice, designed to protect against oral [...]

    January 20, 2026
  • Clinical Trials,Data Management,Digital Health,Technology and platforms

    Zeroport raises $10 million seed to address remote access security risks in pharma and clinical trials

    Zeroport has raised $10 million in seed funding to expand [...]

    January 20, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top